Biomedicine, Biotechnology and Public Health Department, University of Cadiz, Cadiz, 11002, Spain.
Biomedical Research and Innovation Institute of Cadiz (INiBICA), Cadiz, 11002, Spain.
J Biomed Sci. 2024 Jul 15;31(1):71. doi: 10.1186/s12929-024-01059-w.
Critical limb-threatening ischemia (CLTI) constitutes the most severe manifestation of peripheral artery disease, usually induced by atherosclerosis. CLTI patients suffer from high risk of amputation of the lower extremities and elevated mortality rates, while they have low options for surgical revascularization due to associated comorbidities. Alternatively, cell-based therapeutic strategies represent an effective and safe approach to promote revascularization. However, the variability seen in several factors such as cell combinations or doses applied, have limited their success in clinical trials, being necessary to reach a consensus regarding the optimal "cellular-cocktail" prior further application into the clinic. To achieve so, it is essential to understand the mechanisms by which these cells exert their regenerative properties. Herein, we have evaluated, for the first time, the regenerative and vasculogenic potential of a combination of endothelial colony forming cells (ECFCs) and mesenchymal stem cells (MSCs) isolated from adipose-tissue (AT), compared with ECFCs from umbilical cord blood (CB-ECFCs) and AT-MSCs, in a murine model of CLTI.
Balb-c nude mice (n:32) were distributed in four different groups (n:8/group): control shams, and ischemic mice (after femoral ligation) that received 50 µl of physiological serum alone or a cellular combination of AT-MSCs with either CB-ECFCs or AT-ECFCs. Follow-up of blood flow reperfusion and ischemic symptoms was carried out for 21 days, when mice were sacrificed to evaluate vascular density formation. Moreover, the long-term molecular changes in response to CLTI and both cell combinations were analyzed in a proteomic quantitative approach.
AT-MSCs with either AT- or CB-ECFCs, promoted a significant recovery of blood flow in CLTI mice 21 days post-ischemia. Besides, they modulated the inflammatory and necrotic related processes, although the CB group presented the slowest ischemic progression along the assay. Moreover, many proteins involved in the repairing mechanisms promoted by cell treatments were identified.
The combination of AT-MSCs with AT-ECFCs or with CB-ECFCs promoted similar revascularization in CLTI mice, by restoring blood flow levels, together with the modulation of the inflammatory and necrotic processes, and reduction of muscle damage. The protein changes identified are representative of the molecular mechanisms involved in ECFCs and MSCs-induced revascularization (immune response, vascular repair, muscle regeneration, etc.).
严重肢体缺血(CLI)是外周动脉疾病(PAD)最严重的表现形式,通常由动脉粥样硬化引起。CLI 患者下肢截肢风险高,死亡率高,由于合并症,手术血运重建的选择有限。相反,基于细胞的治疗策略代表了促进血运重建的有效和安全方法。然而,由于细胞组合或应用剂量等多种因素的差异,它们在临床试验中的成功率有限,因此有必要在进一步应用于临床之前就最佳“细胞鸡尾酒”达成共识。为此,必须首先了解这些细胞发挥其再生特性的机制。在此,我们首次评估了源自脂肪组织(AT)的内皮祖细胞(ECFCs)和间充质干细胞(MSCs)组合与源自脐带血(CB-ECFCs)的 ECFCs 和 AT-MSCs 相比,在 CLI 小鼠模型中的再生和血管生成潜力。
将 Balb-c 裸鼠(n:32)分为四组(n:8/组):对照组和缺血组(股动脉结扎后),缺血组在 21 天的随访期间,接受 50μl 的生理血清或单独或 AT-MSCs 与 CB-ECFCs 或 AT-ECFCs 的细胞组合。评估血管密度形成后,对血流再灌注和缺血症状进行了 21 天的监测,随后处死小鼠以评估血管密度形成。此外,还采用蛋白质组学定量方法分析了对 CLI 和两种细胞组合的长期分子变化。
源自 AT 的 MSC 与源自 AT 或 CB 的 ECFCs 联合,可在缺血后 21 天内显著恢复 CLI 小鼠的血流。此外,它们还调节了与炎症和坏死相关的过程,尽管 CB 组在整个实验过程中表现出最慢的缺血进展。此外,还鉴定出许多与细胞治疗促进的修复机制相关的蛋白质。
源自 AT 的 MSC 与源自 AT 的 ECFCs 或源自 CB 的 ECFCs 的组合可通过恢复血流水平,同时调节炎症和坏死过程,减少肌肉损伤,在 CLI 小鼠中促进类似的血管生成。鉴定出的蛋白质变化代表了 ECFCs 和 MSCs 诱导的血管生成(免疫反应、血管修复、肌肉再生等)涉及的分子机制。